Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ISR's Cash to Debt is ranked higher than
97% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.03 vs. ISR: No Debt )
ISR' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: No Debt

Equity to Asset 0.92
ISR's Equity to Asset is ranked higher than
98% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. ISR: 0.92 )
ISR' s 10-Year Equity to Asset Range
Min: -1.18   Max: 0.92
Current: 0.92

-1.18
0.92
F-Score: 3
Z-Score: 23.19
M-Score: -2.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -107.11
ISR's Operating margin (%) is ranked lower than
52% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.92 vs. ISR: -107.11 )
ISR' s 10-Year Operating margin (%) Range
Min: -360.83   Max: -10.59
Current: -107.11

-360.83
-10.59
Net-margin (%) -130.10
ISR's Net-margin (%) is ranked lower than
51% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.36 vs. ISR: -130.10 )
ISR' s 10-Year Net-margin (%) Range
Min: -412.14   Max: -12.01
Current: -130.1

-412.14
-12.01
ROE (%) -26.99
ISR's ROE (%) is ranked higher than
56% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.53 vs. ISR: -26.99 )
ISR' s 10-Year ROE (%) Range
Min: -659.02   Max: -40.65
Current: -26.99

-659.02
-40.65
ROA (%) -24.33
ISR's ROA (%) is ranked higher than
55% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. ISR: -24.33 )
ISR' s 10-Year ROA (%) Range
Min: -6600   Max: 23500
Current: -24.33

-6600
23500
ROC (Joel Greenblatt) (%) -126.24
ISR's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. ISR: -126.24 )
ISR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -876.37   Max: -6.64
Current: -126.24

-876.37
-6.64
Revenue Growth (3Y)(%) -21.90
ISR's Revenue Growth (3Y)(%) is ranked higher than
53% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ISR: -21.90 )
ISR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 12.2
Current: -21.9

0
12.2
EBITDA Growth (3Y)(%) 14.50
ISR's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 225 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ISR: 14.50 )
ISR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 205.5
Current: 14.5

0
205.5
EPS Growth (3Y)(%) 13.30
ISR's EPS Growth (3Y)(%) is ranked higher than
80% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. ISR: 13.30 )
ISR' s 10-Year EPS Growth (3Y)(%) Range
Min: -67.8   Max: 233.2
Current: 13.3

-67.8
233.2
» ISR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ISR Guru Trades in Q1 2014

Jeff Auxier 14,218 sh (New)
» More
Q2 2014

ISR Guru Trades in Q2 2014

Jeff Auxier 14,218 sh (unchged)
» More
Q3 2014

ISR Guru Trades in Q3 2014

Jeff Auxier 14,218 sh (unchged)
» More
Q4 2014

ISR Guru Trades in Q4 2014

Jeff Auxier 14,218 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 23.70
ISR's Forward P/E is ranked higher than
81% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 33.56 vs. ISR: 23.70 )
N/A
P/B 4.05
ISR's P/B is ranked higher than
65% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. ISR: 4.05 )
ISR' s 10-Year P/B Range
Min: 0.31   Max: 55
Current: 4.05

0.31
55
P/S 18.44
ISR's P/S is ranked lower than
52% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.99 vs. ISR: 18.44 )
ISR' s 10-Year P/S Range
Min: 0.56   Max: 285
Current: 18.44

0.56
285
Current Ratio 13.61
ISR's Current Ratio is ranked higher than
98% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. ISR: 13.61 )
ISR' s 10-Year Current Ratio Range
Min: 0.82   Max: 24.59
Current: 13.61

0.82
24.59
Quick Ratio 13.18
ISR's Quick Ratio is ranked higher than
98% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.79 vs. ISR: 13.18 )
ISR' s 10-Year Quick Ratio Range
Min: 0.68   Max: 24.21
Current: 13.18

0.68
24.21
Days Inventory 33.26
ISR's Days Inventory is ranked higher than
95% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.27 vs. ISR: 33.26 )
ISR' s 10-Year Days Inventory Range
Min: 2.2   Max: 64.02
Current: 33.26

2.2
64.02
Days Sales Outstanding 69.40
ISR's Days Sales Outstanding is ranked higher than
71% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.40 vs. ISR: 69.40 )
ISR' s 10-Year Days Sales Outstanding Range
Min: 0.98   Max: 109.1
Current: 69.4

0.98
109.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 8.30
ISR's Price/Net Current Asset Value is ranked higher than
86% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. ISR: 8.30 )
ISR' s 10-Year Price/Net Current Asset Value Range
Min: 0.71   Max: 175
Current: 8.3

0.71
175
Price/Tangible Book 4.05
ISR's Price/Tangible Book is ranked higher than
77% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. ISR: 4.05 )
ISR' s 10-Year Price/Tangible Book Range
Min: 0.35   Max: 51.79
Current: 4.05

0.35
51.79
Price/Median PS Value 3.46
ISR's Price/Median PS Value is ranked higher than
50% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. ISR: 3.46 )
ISR' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 46.36
Current: 3.46

0.12
46.36
Earnings Yield (Greenblatt) -5.00
ISR's Earnings Yield (Greenblatt) is ranked higher than
57% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. ISR: -5.00 )
ISR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.9   Max: 16057.5
Current: -5

5.9
16057.5

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 6 14 22 31
EPS($) -0.04 0.07 0.17 0.26
EPS without NRI($) -0.04 0.07 0.17 0.26

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
IsoRay, Inc. was organized under Minnesota law in 1983, formerly known as Century Park Pictures Corporation On July 28, 2005, Century changed its name to IsoRay, Inc. The Company provides treatment for all solid tumor applications using Cesium-131 (Cs-131). Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; and breast, liver, brain and pancreatic cancer. The professional and patient market segments each play a role in the ultimate choice of cancer treatment and the specific isotope chosen for seed brachytherapy treatment. In August 2009, IsoRay Medical obtained treatment for Proxcelan(tm) Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided strands. Brachytherapy seeds are small devices used in a radiation procedure. IsoRay markets the Proxcelan Cs-131 brachytherapy seed for the treatment of prostate cancer, ocular melanomas, and head and neck cancers, and intends to market Cs-131 for the treatment of other malignant disease, such as lung, in the near future. The Company competes with both public and private medical device, biotechnology and pharmaceutical companies. The disposal of certain radioactive substances and wastes are subject to regulation by several federal and state agencies depending on the nature of the substance or waste material.
» More Articles for ISR

Headlines

Articles On GuruFocus.com
ciazek stock Mar 28 2015 
UPMC Study Reports IsoRay's Cesium-131 Prostate Treatment Provides Strong Cancer Control With Lower Jan 20 2015 
IsoRay's Cesium-131 Therapy Takes Center Stage at Russia's Neftyanik Hospital a Center of Excellence Jan 13 2015 
IsoRay Ranked 5th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed o Jan 12 2015 
IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer Dec 08 2014 
IsoRay Inc. Reports Operating Results (10-K) Sep 28 2010 
IsoRay Inc. Reports Operating Results (10-Q) May 12 2010 
IsoRay Inc. Reports Operating Results (10-Q) Nov 12 2009 
IsoRay Inc. Reports Operating Results (10-Q/A) Sep 02 2009 
IsoRay Inc. Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
Gynecologic Cancers Successfully Treated Using IsoRay’s Cesium-131 will be Presented by Dr.... Mar 24 2015
Gynecologic Cancers Successfully Treated Using IsoRay's Cesium-131 Will Be Presented by Dr. Jonathan... Mar 24 2015
ISORAY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 02 2015
Biotech Making A Comeback - Here Is One Stock to Watch Feb 26 2015
ISORAY, INC. Financials Feb 24 2015
10-Q for IsoRay, Inc. Feb 19 2015
ISORAY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 18 2015
IsoRay, Inc. Reports Second Quarter Results Feb 18 2015
ISORAY, INC. Files SEC form 10-Q, Quarterly Report Feb 17 2015
WSA Medical Spotlight Feb 17 2015
Shifts In Government Policy Create Potential Surge For Medical Device Leader Pressure Biosciences,... Feb 10 2015
UPMC Study Reports Isoray's Cesium-131 Prostate Treatment Provides Strong Cancer Control with Lower... Jan 20 2015
Tuesday's Morning Movers: FXCM Takes Another Big Drop Jan 20 2015
UPMC Study Reports IsoRay's Cesium-131 Prostate Treatment Provides Strong Cancer Control With Lower... Jan 20 2015
IsoRay's Cesium-131 Therapy Takes Center Stage AT Russia's Neftyanik Hospital a Center of Excellence... Jan 13 2015
IsoRay Ranked 5Th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed... Jan 13 2015
IsoRay's Cesium-131 Therapy Takes Center Stage at Russia's Neftyanik Hospital a Center of Excellence... Jan 13 2015
IsoRay Ranked 5th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed... Jan 12 2015
IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer Dec 08 2014
IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer Dec 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK